What You Should Know:
– Glytec, a provider of an AI-powered technology platform for diabetes and related conditions, secures a $36M growth investment led by Savitr Capital and Hayfin Capital Management.
– The funding will fuel the continued expansion of Glytec’s platform, including its flagship Glucommander® SaaS solution, and accelerate the development of innovative new technologies. The investment comes as healthcare systems face increasing pressure to improve inpatient glycemic control, with new CMS quality measures set to hold hospitals accountable for performance.
Addressing a Growing Health Crisis
The incidence of diabetes and its associated conditions continues to escalate, placing an immense burden on the healthcare system. Over one-third of all hospitalized patients require insulin therapy, yet management of high blood sugar remains a significant challenge.
Each year, more than 2 million patients experience an adverse event in the hospital leading to hypoglycemia, costing the healthcare system over $8 billion and contributing to longer lengths of stay and increased readmissions. Despite these risks, nearly one-third of hospitals have no glucose management metrics, and 59% lack an automated method for tracking hyperglycemia and hypoglycemia rates.
Inpatient Glycemic Management
Glytec’s flagship product, Glucommander®, is the leading cloud-based SaaS solution for inpatient glycemic management. It is the first-ever FDA-cleared cloud-based insulin management software and is trusted by over 400 hospitals nationwide to improve patient safety, reduce costs, and increase revenue. he new capital will be used to expand R&D initiatives, scale the platform, and attract top-tier talent.
“This investment is a pivotal moment for Glytec, validating our vision of a future where deep data-driven insights empower clinicians to deliver highly individualized and proactive care for diabetes and metabolic conditions,” said Patrick Cua, CEO of Glytec. “Savitr Capital and Hayfin Capital share our belief in the transformative power of technology to improve patient outcomes and alleviate the burden of complex chronic diseases.”
